Abdel 2011.

Study characteristics
Methods	Study design: RCT Unit of randomisation: No information Total duration of study: 12 weeks Run‐in period: No information Intervention time: No information Follow‐up: No information Setting: Beni‐Suef University, Beni‐Suef, Egypt
Participants	Type of heart failure: CHF N = 100 participants (ivabradine: 50; placebo: 50) Mean age: No information Gender: No information Severity of condition: LV dysfunction EF < 35% Inclusion criteria: Sinus rhythm HR > 80 bpm Symptomatic heart failure (NYHA class II and III) Left ventricular systolic dysfunction (EF < 35%) Patients in sinus rhythm (HR > 80 bpm) with symptomatic heart failure (NYHA class II and III) despite optimal medical therapy who were proved to have left ventricular systolic dysfunction (EF < 35%) secondary to ischaemic or idiopathic cardiomyopathy Exclusion criteria: No information Withdrawals: No information
Interventions	Intervention: Ivabradine max. 5 to 7.5 mg twice a day Comparison: Placebo Concomitant medications: No information Excluded medications: No information
Outcomes	Outcomes and time points measured in the study: [Day 0, 12 weeks] Change in the exercise duration on treadmill Change in echocardiographic parameters Conclusion: "Ivabradine therapy for 12 weeks when added to optimum medical therapy in patients with left ventricular systolic dysfunction secondary to ischaemic or idiopathic cardiomyopathy increased significantly the exercise duration and functional capacity. It also decreased significantly the resting HR and peak HR during exercise testing with trends towards increase in (2D) EF but it did not reach statistical significance."
Notes	Funding for trial: No information Notable conflicts of interest of authors: No information Contact to authors/unpublished data: We contacted Yasser A Abdel‐Hadi via email on 22 November 2018 to inquire about funding, way of randomisation, age, sex, duration IP, and missing data. We did not receive an answer.
Risk of bias
Bias	Authors' judgement	Support for judgement
Random sequence generation (selection bias)	Unclear risk	Insufficient information to base judgement
Allocation concealment (selection bias)	Unclear risk	Insufficient information to base judgement
Blinding of participants and personnel (performance bias) All outcomes	Unclear risk	Insufficient information to base judgement
Blinding of outcome assessment (detection bias) All outcomes	Unclear risk	Insufficient information to base judgement
Incomplete outcome data (attrition bias) All outcomes	Unclear risk	Insufficient information to base judgement
Selective reporting (reporting bias)	Unclear risk	Insufficient information to base judgement
Other bias	Unclear risk	Insufficient information to base judgement